Jubilant Life Science sparkles after ANDA approval

Jubilant Life Sciences has received Abbreviated New Drug Application (ANDA) final approval for Felodipine Extended-Release Tablets USP, 2.5 mg, 5 mg, and 10 mg. These tablets are the generic version of Plendil Tablets of AstraZeneca. The company also bagged ANDA final approval for Telmisartan Tablets, USP 20,40 and 80mg, the generic version of Micardis Tablets of Boehringer Ingelheim Pharmaceuticals Inc.

As on June 30, 2016, Jubilant Life Sciences had a total of 770 filings for Oral Solids of which 578 have been approved in various regions globally. This includes 70 ANDAs filed in the US of which 44 have been approved and 104 filings in Europe also have been in its kitty.

The share price of Jubilant Life science increased by 4.63 per cent on bourses in early trades on Thursday and is trading at Rs 524 on an  intra-day basis.

Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients.